1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
INVO Bioscience, Inc.

INVO Bioscience, Inc.

INVO
INVO Bioscience, Inc.US flagNASDAQ Capital Market
0.83
USD
-0.02
- -
3.25MMarket Cap

Total Valuation

INVO Bioscience, Inc. carries a market capitalization of 3.25M, placing it among publicly traded companies globally. Its enterprise value stands at 15.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.25M
Enterprise Value15.18M

Share Statistics

INVO Bioscience, Inc. currently has 3.91M shares outstanding.

Shares Outstanding3.91M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.43, and the price-to-book ratio stands at -0.04.

PE RatioN/A
PS Ratio0.43
PB Ratio-0.04
P/TBV Ratio-0.16
P/FCF Ratio-0.92
P/OCF Ratio-0.87

Enterprise Valuation

EV / Sales2.44
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

INVO Bioscience, Inc. maintains a current ratio of 0.23, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -22,882.39, indicating conservative leverage, while an interest coverage ratio of -4.80 demonstrates limited ability to service its debt obligations.

Current Ratio0.23
Quick Ratio0.08
Debt / Equity-22,882.39
Debt / EBITDA-1.10
Interest Coverage-4.80

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-40.92
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover14.47

Taxes

Income Tax54,130.00
Effective Tax RateN/A

Stock Price Statistics

INVO Bioscience, Inc.'s stock has declined approximately -51.56977% over the past 52 weeks. The 50-day moving average sits at 0.77, while the 200-day moving average is 0.90.

Beta (5Y)N/A
52-Week Price Change-51.56977%
50-Day Moving Average0.77
200-Day Moving Average0.90
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, INVO Bioscience, Inc. generated 6.23M in revenue and converted that into -7.47M in net income, yielding earnings per share of -1.98. EBITDA reached -4.83M, while operating income came in at -5.66M.

Revenue6.23M
Gross Profit2.64M
Operating Income-5.66M
Pretax Income-7.41M
Net Income-7.47M
EBITDA-4.83M
EBIT-5.66M
Earnings Per Share (EPS)-1.98

Balance Sheet

INVO Bioscience, Inc. holds 471,591.00 in cash and equivalents against 5.34M in total debt, resulting in a net debt position of 2.38M. Total book value stands at -63.54M, with working capital of -6.70M providing operational flexibility.

Cash & Cash Equivalents471,591.00
Total Debt5.34M
Net Debt2.38M
Equity (Book Value)-63.54M
Book Value Per Share-16.87
Working Capital-6.70M

Cash Flow

INVO Bioscience, Inc. produced -3.07M in operating cash flow over the past twelve months. After subtracting -179,829.00 in capital expenditures, free cash flow totaled -3.25M - equivalent to -0.86 per share.

Operating Cash Flow-3.07M
Capital Expenditures-179,829.00
Free Cash Flow-3.25M
FCF Per Share-0.86

Margins

INVO Bioscience, Inc. operates with a gross margin of 42.40, reflecting its pricing power and cost economics. The operating margin of -90.85 and net profit margin of -119.90 provide insight into operational efficiency.

Gross Margin42.40
Operating Margin-90.85
Pretax Margin-119.03
Profit Margin-119.90
EBITDA Margin-77.54

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-92.90
FCF Yield-108.16

Stock Splits

INVO Bioscience, Inc.'s most recent stock split took place on July 28, 2023 with a 20:1 split ratio.

Last Split Date7/28/2023
Split Ratio20:1

Scores

INVO Bioscience, Inc. posts an Altman Z-Score of -14.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-14.19